Corium International Company Profile (NASDAQ:CORI)

Corium International trades on the NASDAQ under the ticker symbol "CORI."

Corium International, Inc. (NASDAQ:CORI) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The business had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. View Corium International's Earnings History.

7 brokers have issued 12-month price targets for Corium International's stock. Their predictions range from $10.00 to $16.00. On average, they anticipate Corium International's stock price to reach $13.14 in the next twelve months. View Analyst Ratings for Corium International.

Here are some recent quotes from research analysts about Corium International stock:

• 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (10/10/2017)
• 2. Cantor Fitzgerald analysts commented, "CORI continues to make progress on the donepezil patch, which we believe could be an important new Alzheimer’s therapy with pivotal top-line data that demonstrate bioequivalence and reduced GI side effects." (9/27/2017)
• 3. Jefferies Group LLC analysts commented, "CORI posted a slightly narrower than expected loss (-$10.4M vs -$11.2M JEF). Key pipeline product donepezil TD finished the 2nd of three stages of the pilot study and remains on track to start the pivotal Ph 3 study in 2H17. Partners P&G and AGRX continue to support the topline but a new partnership remains key for FY17 in order for mgt to remain credible and generate much needed non-dilutive financing." (2/15/2017)
• 4. Needham & Company LLC analysts commented, "CORI reported FY1Q17 financials and provided a development update for its Alzheimer's disease transdermal patch programs. The second treatment period of the ongoing pilot BE study for the donepezil patch recently completed and the first interim results are expected in March. The upcoming interim look could provide the initial derisking for the Corplex CNS patch program. CORI recently completed a $20MM equity raise that extends the cash runway into late-2017/ early-2018. We maintain our Buy rating and adjust our $PT to $10 (from $12) to reflect the new higher share count and expected volatility in revenues from partnered products." (2/14/2017)
• 5. FBR & Co analysts commented, "Corium reported below-consensus revenue and EPS after the market close on November 21. While EPS and revenues were disappointing in the quarter, we believe that investors should continue to focus on the company’s impressive CNS patch pipeline. Corium has received favorable written feedback from the FDA regarding its development of Corplex donepezil and Corplex memantine. The FDA has indicated that if Corium can demonstrate bioequivalence between its products and oral Aricept (donepezil) and oral Namenda XR (memantine) in bioequivalence (BE) studies, then it could submit a 505(b)(2) NDA without conducting additional clinical efficacy trials. We believe meaningful catalysts are ahead in 2017. Patient dosing started in September for a pilot study for Corplex donepezil in preparation for the pivotal BE trial in 2H17." (11/22/2016)

Some companies that are related to Corium International include AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Marinus Pharmaceuticals (MRNS), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK) and Concordia International Corp. (CXRX).

Corium International's management team includes the folowing people:

• David L. Greenwood, Chairman of the Board
• Peter D. Staple, President, Chief Executive Officer, Director
• Robert S. Breuil, Chief Financial Officer
• Parminder Singh Ph.D., Chief Technology Officer, Vice President - Research & Development
• Joseph J. Sarret M.D. J.D., Chief Business Officer
• Robert W. Thomas, Lead Independent Director
• Eric H. Bjerkholt, Independent Director
• Bhaskar Michael Chaudhuri Ph.D., Independent Director
• Ronald W. Eastman, Independent Director
• Phyllis I. Gardner M.D., Independent Director

Shares of Corium International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Corium International stock can currently be purchased for approximately $10.26.